CBRE Group Inc
Change company Symbol lookup
Select an option...
CBRE CBRE Group Inc
VNT Vontier Corp
GBBEF.SO Barclays Bank PLC
GLDI Credit Suisse X-Links Gold Shares Covered Call ETN
BILL Bill.com Holdings Inc
AUB Atlantic Union Bankshares Corp
TSM Taiwan Semiconductor Manufacturing Co Ltd
STNG Scorpio Tankers Inc
FFIE Faraday Future Intelligent Electric Inc
SSBI Summit State Bank
Go

Real Estate : Real Estate Management & Development | Mid Cap Blend
Company profile

CBRE Group, Inc. is a holding company. The Company's Advisory Services segment provides a range of services globally, including property leasing, property sales, mortgage services, property management services and valuation services. The Global Workplace Solutions segment provides a suite of integrated, contractually based outsourcing services to occupiers of real estate, including facilities management and project management. The Real Estate Investments includes segment investment management services provided globally; development services in the United States, United Kingdom and Continental Europe, and legacy flexible office space solutions. The Company provides services to real estate investors and occupiers. Its services include capital markets, property leasing, investment management, property management, valuation and development services, among others. The Company also provides expert technical support services for high-end laboratory systems in the United States.

Closing Price
$77.28
Day's Change
0.50 (0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
77.64
Day's Low
76.41
Volume
(Light)
Volume:
589,000

10-day average volume:
1,397,597
589,000

FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. With Losses of $75,000 to Contact the Firm

6:15 pm ET October 3, 2022 (Accesswire) Print

LOS ANGELES, CA / ACCESSWIRE / October 3, 2022 /The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kiromic BioPharma, Inc. ("Kiromic" or "the Company") (NASDAQ:KRBP) for violations of the federal securities laws.

The Schall Law Firm, Monday, October 3, 2022, Press release picture

Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted on July 2, 2021 (the "IPO"), and/or between June 25, 2021 and August 13, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before October 4, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Kiromic received communications from the FDA on June 16 and 17, 2021, placing a clinical hold on its two candidate products. The Company failed to inform investors of this clinical hold despite the fact it learned of the hold before the IPO occurred. The Company's IPO offering documents stated that clinical testing would move forward in the third quarter of 2021. The Company did not proceed with this test due to the clinical hold. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Kiromic, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE: The Schall Law Firm





View source version on accesswire.com:

https://www.accesswire.com/718657/FINAL-DEADLINE-TOMORROW-The-Schall-Law-Firm-Encourages-Investors-in-Kiromic-BioPharma-Inc-With-Losses-of-75000-to-Contact-the-Firm



comtex tracking

COMTEX_415836018/2457/2022-10-03T18:15:15

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.